Effectiveness of Aquamin® in Mitigating Halitosis

This is an interventional treatment trial for Healthy focused on measuring Aquamin® Read More

Inclusion Criteria:

• Must be able to give written informed consent
• Willing to follow study procedures of no eating, drinking, toothbrushing, smoking or using mouth rinse 60 minutes before study visits
• Willing to not scrape their tongue with a toothbrush, oral hygiene aid, or other utensil during the study participation
• Periodontally stable
• Self-reported halitosis
• A negative pregnancy test for pre-menopausal women with intact female reproductive organs, and subject must agree to use appropriate birth control over the study period.

Exclusion Criteria:

• Pregnant or lactating women
• Participating in any other interventional trials using an investigational drug
• Diagnosed with any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors) or active gastric / duodenal ulcers - peptic ulcer disease (in last 3 months) or with severe symptoms of ulcerative colitis or Crohn's disease
• Any gastrointestinal or colonic malignancy- Kidney disease, including kidney "stones" or hypercalcemia
• Coagulopathy/hereditary hemorrhagic disorders/or receiving therapeutic doses of Coumadin or heparin
• Presence of one or more cavitated carious lesions, untreated dental abscesses (endodontic or periodontal), untreated periodontitis (gum disease), or oral pathologies that may contribute to oral malodor (e.g., candidiasis, erosive gingival conditions)
• Taking any of the following within 30 days (will be eligible after completing 30 days of wash out period):

Calcium; Vitamin D, including multivitamins that have low amounts of calcium/Vitamin D supplements; Oral steroids; Non-steroidal anti-inflammatory medications (NSAIDS); Antibiotics.